[HTML][HTML] Polyunsaturated fatty acids and their potential therapeutic role in cardiovascular system disorders—a review
E Sokoła-Wysoczańska, T Wysoczański, J Wagner… - Nutrients, 2018 - mdpi.com
Cardiovascular diseases are described as the leading cause of morbidity and mortality in
modern societies. Therefore, the importance of cardiovascular diseases prevention is widely …
modern societies. Therefore, the importance of cardiovascular diseases prevention is widely …
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy
SA Scott, K Sangkuhl, EE Gardner… - Clinical …, 2011 - Wiley Online Library
CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet
prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19* 2 (c. 681G> A; …
prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19* 2 (c. 681G> A; …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
LH Cavallari, CR Lee, AL Beitelshees… - JACC: Cardiovascular …, 2018 - jacc.org
Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping
JS Schildcrout, JC Denny, E Bowton… - Clinical …, 2012 - Wiley Online Library
Routine integration of genotype data into drug decision making could improve patient safety,
particularly if many relevant genetic variants can be assayed simultaneously before …
particularly if many relevant genetic variants can be assayed simultaneously before …
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy
CYP2C19 genotype‐guided antiplatelet therapy following percutaneous coronary
intervention is increasingly implemented in clinical practice. However, challenges such as …
intervention is increasingly implemented in clinical practice. However, challenges such as …
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary …
MD Klein, AK Williams, CR Lee… - … , and Vascular Biology, 2019 - Am Heart Assoc
Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary …
prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary …
Clinically relevant genetic variations in drug metabolizing enzymes
N Pinto, M Eileen Dolan - Current drug metabolism, 2011 - ingentaconnect.com
In the field of pharmacogenetics, we currently have a few markers to guide physicians as to
the best course of therapy for patients. For the most part, these genetic variants are within a …
the best course of therapy for patients. For the most part, these genetic variants are within a …
[HTML][HTML] Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
AB Nguyen, LH Cavallari, JS Rossi… - Frontiers in …, 2022 - frontiersin.org
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and
aspirin remains the standard of care for all patients undergoing percutaneous coronary …
aspirin remains the standard of care for all patients undergoing percutaneous coronary …
Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
CR Lee, VB Sriramoju, A Cervantes… - Circulation: Genomic …, 2018 - Am Heart Assoc
Background: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after
percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of …
percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of …